Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase II clinical trials for the treatment of solid tumors, including renal, head and neck, ovarian and triple negative breast cancers; and Modi-2, which targets stress-induced post translational modifications, such as homocittrullination. In addition, the company provides GlyMab platform that generates various affinity tumour specific monoclonal antibodies (mAb) targeting glycans that are over-expressed on cancer cells; and AvidiMab, which romotes receptor clustering thereby improving immune signalling. Scancell Holdings plc was founded in 1996 and is based in Oxford, the United Kingdom.
Frequently asked questions
What sector does Scancell Holdings plc (SCNLF) operate in?
Scancell Holdings plc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Scancell Holdings plc (SCNLF) current stock price?
As of the latest data, Scancell Holdings plc stock price is $1.41, with a previous close of $1.41.
What is Scancell Holdings plc (SCNLF) current market capitalization?
Scancell Holdings plc market cap is approximately 1.91 billion.
What is Scancell Holdings plc (SCNLF) Earnings Per Share (EPS)?
The trailing EPS is -$0.23.
What is Scancell Holdings plc (SCNLF) EBITDA?
Scancell Holdings plc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -8.19 million.
Does Scancell Holdings plc (SCNLF) pay dividends?
No. Scancell Holdings plc does not pay a dividend.
What is Scancell Holdings plc (SCNLF) beta (volatility) score?
Scancell Holdings plc has a beta of 0.689, indicating lower volatility than the overall market.
